HUP0001271A1 - Eljárás rekombináns adenovírusok előállítására - Google Patents

Eljárás rekombináns adenovírusok előállítására

Info

Publication number
HUP0001271A1
HUP0001271A1 HU0001271A HUP0001271A HUP0001271A1 HU P0001271 A1 HUP0001271 A1 HU P0001271A1 HU 0001271 A HU0001271 A HU 0001271A HU P0001271 A HUP0001271 A HU P0001271A HU P0001271 A1 HUP0001271 A1 HU P0001271A1
Authority
HU
Hungary
Prior art keywords
bis
purification
adenovirus
recombinant adenovirus
producing recombinant
Prior art date
Application number
HU0001271A
Other languages
English (en)
Inventor
Francis Blanche
Jean-Marc Guillaume
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9608164A external-priority patent/FR2750433B1/fr
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP0001271A1 publication Critical patent/HUP0001271A1/hu
Publication of HUP0001271A3 publication Critical patent/HUP0001271A3/hu
Publication of HU224558B1 publication Critical patent/HU224558B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgya eljárás rekőmbináns adenővírűsők tisztítására,melynek sőrán a vírűs-DNS-t részecskeképző sejtek tenyészetébe vezetikbe, és a termelt vírűsőkat a felülúszóba való felszabadűlás űtánaratják le. A találmány tárgya a termelt vírűsőkat tartalmazókészítmény is, valamint egy eljárás rekőmbináns adenővírűstisztítására egy biőlógiai közegből, amely tartalmaz egy erősaniőncserélő krőmatőgráfiás tisztítási lépést. ŕ
HU0001271A 1996-07-01 1997-06-20 Eljárás rekombináns adenovírusok tisztítására HU224558B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9608164A FR2750433B1 (fr) 1996-07-01 1996-07-01 Procede de production d'adenovirus recombinants
US2666796P 1996-09-25 1996-09-25
PCT/FR1997/001107 WO1998000524A1 (fr) 1996-07-01 1997-06-20 Procede de production d'adenovirus recombinants

Publications (3)

Publication Number Publication Date
HUP0001271A1 true HUP0001271A1 (hu) 2000-08-28
HUP0001271A3 HUP0001271A3 (en) 2002-01-28
HU224558B1 HU224558B1 (hu) 2005-10-28

Family

ID=26232805

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001271A HU224558B1 (hu) 1996-07-01 1997-06-20 Eljárás rekombináns adenovírusok tisztítására

Country Status (13)

Country Link
US (3) US6485958B2 (hu)
EP (1) EP0944717A1 (hu)
JP (1) JP2000514290A (hu)
KR (1) KR20050043996A (hu)
AU (1) AU3447097A (hu)
BR (1) BR9710030A (hu)
CA (1) CA2258158A1 (hu)
CZ (1) CZ438398A3 (hu)
HU (1) HU224558B1 (hu)
IL (1) IL127692A0 (hu)
NO (1) NO986202L (hu)
SK (1) SK181098A3 (hu)
WO (1) WO1998000524A1 (hu)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625279A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6485958B2 (en) * 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
AU5370598A (en) 1996-12-13 1998-07-03 Schering Corporation Methods for purifying viruses
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) * 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2328462C (en) 1998-04-22 2010-11-09 Genvec, Inc. Efficient purification of adenovirus
AU770672B2 (en) * 1998-05-27 2004-02-26 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
IL143381A0 (en) * 1998-12-31 2002-04-21 Aventis Pharma Sa Method for separating viral particles
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
ES2564553T3 (es) * 2001-08-08 2016-03-23 The Trustees Of The University Of Pennsylvania Procedimiento para purificar vectores víricos que tienen proteínas que se unen a ácido siálico
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
CN1617745A (zh) * 2002-01-18 2005-05-18 舍林股份公司 稳定的腺病毒配方
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2509973C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) * 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
US20040229335A1 (en) 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
CA2529053A1 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
JP2007522814A (ja) * 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
WO2006052302A2 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
US8900804B2 (en) * 2004-11-22 2014-12-02 Cedars-Sinai Medical Center Methods and solutions for tissue preservation
US7488848B2 (en) 2005-03-21 2009-02-10 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
ES2317517T5 (es) * 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
AU2008209759B2 (en) 2007-01-30 2013-03-21 Transgene S.A. Papillomavirus E2 polypeptide used for vaccination
ES2670813T3 (es) 2007-06-21 2018-06-01 Alphavax, Inc. Partículas de replicón de alfavirus para uso en vacunación
MX2011004292A (es) * 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
PL2488636T3 (pl) 2009-10-15 2014-07-31 Crucell Holland Bv Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
ES2578514T3 (es) 2010-02-15 2016-07-27 Crucell Holland B.V. Método para la producción de vectores adenovíricos
KR101549296B1 (ko) * 2010-04-14 2015-09-01 이엠디 밀리포어 코포레이션 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법
ES2627117T3 (es) 2010-12-09 2017-07-26 Institut Pasteur Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
NZ628385A (en) 2012-03-12 2016-09-30 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
NZ630649A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US20150150963A1 (en) 2012-06-05 2015-06-04 The Australian National University Vaccination with interleukin-4 antagonists
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP2961417A1 (en) * 2013-02-28 2016-01-06 PsiOxus Therapeutics Limited A process for the production of adenovirus
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP2988780B1 (en) 2013-04-25 2018-12-26 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
GB201415579D0 (en) * 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
AU2015279552B2 (en) * 2014-06-27 2021-01-21 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
WO2016030489A2 (en) * 2014-08-27 2016-03-03 Psioxus Therapeutics Limited A process for the production of adenovirus
WO2016114992A2 (en) 2015-01-13 2016-07-21 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3013637A1 (en) * 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017174568A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP7046835B2 (ja) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー 強力でバランスのとれた双方向性プロモーター
DK3464331T3 (da) 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv Stabiliserede præfusions-rsv f-proteiner
BR112018075969A2 (pt) 2016-06-20 2019-04-02 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022521268A (ja) 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995019427A1 (en) 1994-01-12 1995-07-20 Genetic Therapy, Inc. Purification of retroviral vectors
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6485958B2 (en) * 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
IL143381A0 (en) * 1998-12-31 2002-04-21 Aventis Pharma Sa Method for separating viral particles

Also Published As

Publication number Publication date
CZ438398A3 (cs) 1999-03-17
US6485958B2 (en) 2002-11-26
AU3447097A (en) 1998-01-21
SK181098A3 (en) 1999-07-12
BR9710030A (pt) 1999-08-10
JP2000514290A (ja) 2000-10-31
NO986202L (no) 1999-02-15
HU224558B1 (hu) 2005-10-28
US20050287657A1 (en) 2005-12-29
KR20050043996A (ko) 2005-05-11
EP0944717A1 (fr) 1999-09-29
NO986202D0 (no) 1998-12-30
US20030143730A1 (en) 2003-07-31
US20020028497A1 (en) 2002-03-07
CA2258158A1 (fr) 1998-01-08
WO1998000524A1 (fr) 1998-01-08
US6905862B2 (en) 2005-06-14
IL127692A0 (en) 1999-10-28
HUP0001271A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
HUP0001271A1 (hu) Eljárás rekombináns adenovírusok előállítására
AU2127395A (en) Highly efficient production and isolation of viral particles
MX9801072A (es) Metodo para purificar virus por cromatografia.
EP0085111A4 (en) ASSEMBLED SEMI-PLEASANT MEMBRANE, METHOD FOR THE PRODUCTION AND USE THEREOF.
DE3165561D1 (en) Semipermeable composite membranes comprising modified polyvinyl alcohol, process for their preparation and their use
DE3467715D1 (en) Process for producing microfiltration, ultrafiltration or reverse osmosis elements
CA2297938A1 (en) Process for the purification of nutrients from food process streams
ES2088016T3 (es) Procedimiento para la preparacion de glucolipidos purificados mediante un procedimiento de separacion por membrana.
DE3570866D1 (en) Process for the isolation of citric acid
EP0666320A3 (en) Process for the production of alpha-hydroxy acids or alpha-hydroxyamides by microorganisms.
ZA971459B (en) A process for the purification of opacifying contrast agents.
CA2143805A1 (en) Process for the preparation and purification of iodinated contrast agents
CA2143510A1 (en) Method for the Isolation and Purification of Vitamin K-Dependent Proteins
AU2667995A (en) Chimerical peptide-nucleic acid fragment, process for producing the same and its use for appropriately introducing nucleic acids into cell organelles and cells
CA2086455A1 (en) Method and apparatus for brazing
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
AU561976B2 (en) High strength, low carbon, dual phase steel rods and wires and process for making same
ATE172440T1 (de) Verfahren zur reinigung von magnesiumhydroxid
DE59008610D1 (de) Verbundmembran, verfahren zu ihrer herstellung und ihre verwendung.
DE3071618D1 (en) Thermophilic aspartase, processes for producing, culture used, and l-aspartic acid preparation process using the same
HUT38319A (en) Process for preparing optically active azolyl-alpha, beta-unsaturated alcohols
Chen et al. Isolation and characterization of the membrane-bound Mg super (2+)-adenosinetriphosphatase(Mg super (2+)-ATPase) in Acholeplasma laidlawii.
KR920703802A (ko) 리보뉴클레아제 이량체를 만드는 방법
Franzen Energy efficient TMP systems.
DE69015797D1 (de) Verfahren zur herstellung von 3,4,3',4'-substituierten biphenylverbindungen.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050915

MM4A Lapse of definitive patent protection due to non-payment of fees